Cite
The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251.
MLA
Killion, J. J., et al. “The Antitumor Activity of Doxorubicin against Drug-Resistant Murine Carcinoma Is Enhanced by Oral Administration of a Synthetic Staurosporine Analogue, CGP 41251.” Oncology Research, vol. 7, no. 9, 1995, pp. 453–59. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=8835289&authtype=sso&custid=ns315887.
APA
Killion, J. J., Beltran, P., O’Brian, C. A., Yoon, S. S., Fan, D., Wilson, M. R., & Fidler, I. J. (1995). The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251. Oncology Research, 7(9), 453–459.
Chicago
Killion, J J, P Beltran, C A O’Brian, S S Yoon, D Fan, M R Wilson, and I J Fidler. 1995. “The Antitumor Activity of Doxorubicin against Drug-Resistant Murine Carcinoma Is Enhanced by Oral Administration of a Synthetic Staurosporine Analogue, CGP 41251.” Oncology Research 7 (9): 453–59. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=8835289&authtype=sso&custid=ns315887.